No Data
No Data
Selon Biotechnology (SH 688163): Some shareholders collectively increased their shareholding by 0.29% in the company.
On August 15th, Gelunhui reported that Celanese Biomedical (688163.SH) received a notice from the shareholding entity on August 15th, 2024 regarding the completion of the shareholding. From February 26th, 2024 to August 15th, 2024, the shareholding entity accumulated 318,923 shares of the company through the Shanghai Stock Exchange trading system in a centralized bidding manner, accounting for approximately 0.29% of the total share capital of the company. The total amount of the shareholding is RMB 4,543,506.43 (excluding transaction costs), which exceeds the lower limit of the shareholding plan. The shareholding plan has been fully implemented.
Sailun Biology (688163.SH) has not yet reserved technology in synthetic biology.
On August 7th, Gelon Hui reported that Celon Pharma (688163.SH) stated on its interactive platform that the company has not yet made any technological reserves in the field of synthetic biology.
CELGENE (688163.SH): receives proposal for mid-year dividend distribution from one of its controlling shareholders and director, Fan Zhihe, for the year 2024.
On July 16th, Gelonhui reported that Mr. Fan Zhihe, one of the actual controllers and chairmen of the company, proposed that the board of directors of the company formulate and implement a mid-term dividend plan for 2024 in accordance with the resolution of the shareholder meeting, under the condition of meeting the profit distribution requirement. The proposed dividend amount should not be less than 30% of the net income attributable to the shareholders of the listed company in the first half of 2024.
Salen Biotech (688163.SH) 2023 equity distribution: 0.2 yuan per share, share registration on May 31
Syren Biotech (688163.SH) issued the 2023 equity distribution implementation notice. This time, profits are distributed to Israel...
Syren Biotech (688163.SH) announced first-quarter results, net profit of 1.474,800 yuan, a year-on-year decrease of 51.09%
According to Zhitong Finance App News, Salen Biotech (688163.SH) released its report for the first quarter of 2024. The company's revenue was 263,014 million yuan, up 9.79% year on year; net profit attributable to shareholders of listed companies was 1.474,800 yuan, down 51.09% year on year; net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was 5.7973 million yuan; basic earnings per share were 0.01 yuan/share.
Fan Tiejiong, one of the actual controllers of Syren Biotech (688163.SH), and some executives increased their holdings by a total of 187,300 shares
Syren Biotech (688163.SH) announced that Fan Tiejiong, one of the actual controllers, director and general manager of the company, and vice president...
No Data